An Unusual Skin Infection With Achromobacter xylosoxidans

Crosby, Matthew D; Petropolis, Angelo A.; Mackey, Vernon T; Culpepper, Keliegh S.

doi:10.12788/cutis.0087

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Инфекции дыхательных путей [65][66][67] Инфекции мочевыводящих путей, включая абсцессы почек и паранефральные абсцессы [68][69][70] Инфекции кровотока [71,72] Менингиты, абсцесс мозга [73,74] Абсцессы печени [5] Панкреатиты [75] Раневые инфекции, поражения кожи и подкожной клетчатки [75][76][77] Девайсассоциированные инфекции [78] Эндокардиты [79][80][81] Медиастиниты [4] Поражения ЛОРорганов (синуситы, отиты) [82,83] Поражения органа зрения (эндофтальмиты, кератиты) [84,85] Перитониты, абсцессы брюшной полости и забрюшин ного пространства [86,87] Остеомиелит…”

Section: патология ссылкаunclassified

Enigmatic Achromobacter

Chebotar

Bocharova

2022

CMAC

View full text Add to dashboard Cite

This review aims to describe the microbiological characteristics, resistant features and pathogenic potential of Achromobacter spp. Achromobacter as an opportunistic pathogen can cause severe and even fatal infections. The current knowledge about molecular basis of clinically significant traits of Achromobacter spp. was critically analyzed. The understanding of pathogenicity factors of Achromobacter spp. are largely based on predictive analysis and the role of the most factors was not confirmed by in vivo and in vitro studies. Achromobacter spp. are intrinsically resistant to many groups of antibiotics and can rapidly acquire an adaptive antibiotic resistance. Only three antibiotics (meropenem, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole) have the established breakpoints for Achromobacter spp. There is an unmet need to develop available and accurate methods for species identification of Achromobacter spp.

show abstract

Section: патология ссылкаunclassified

Enigmatic Achromobacter

Chebotar

Bocharova

2022

CMAC

View full text Add to dashboard Cite

show abstract

“…Achromobacter xylosoxidans is an emerging, multidrug-resistant pathogen involved in lung and soft tissue skin infection. It is common in nature and mainly found in water just like P. aeruginosa [8]. To date, there are no recognized co-infections due to P. aeruginosa and A. xylosoxidans in skin and skin appendages.…”

Section: Introductionmentioning

confidence: 99%

Green Nail Syndrome Treated with Ozenoxacin: Two Case Reports

Cosio,

Petruccelli,

Gaziano

et al. 2023

Case Rep Dermatol

View full text Add to dashboard Cite

Green nail syndrome (GNS) is a persistent greenish pigmentation of the nail plate, originally described in 1944 by Goldman and Fox, due to Pseudomonas aeruginosa infection. Recently, pulmonary co-infection of P. aeruginosa and Achromobacter spp. has been described in patients with cystic fibrosis. Achromobacter xylosoxidans is a multidrug-resistant (MDR) pathogen involved in lung and soft tissue skin infections. Both Achromobacter xylosoxidans and P. aeruginosa are mainly found in humid environments or in water. There are no recognized co-infections due to P. aeruginosa and A. xylosoxidans in the skin and appendages. We describe two cases of GNS, the first due to P. aeruginosa associated with Achromobacter xylosoxidans; the other due to MDR P. aeruginosa, both successfully treated with topical ozenoxacin 1% cream daily for 12 weeks. The clinical management of GNS can be confusing, especially when the bacterial culture result is inconsistent or when non-Pseudomonas bacteria are isolated. In our case, due to the co-infection of P. aeruginosa and Achromobacter spp., local treatment with ozenoxacin – the first nonfluorinated quinolone – could be a safe and effective treatment in case of MDR nail infections. Further studies are required to evaluate clinical isolation from nail infections and the co-presence of P. aeruginosa and A. xylosoxidans.

show abstract

“…A large scale biocontamination monitoring found that 10% of the total samples tested were positive for A. xylosoxidans contamination, where the prevalence was stable throughout the investigation time [2]. These bacteria are facultative aerobes, thus their survivability in both aerobic and anaerobic conditions [4].…”

Section: Introductionmentioning

confidence: 99%

Achromobacter xylosoxidans as emerging pathogen in healthcare settings: A mini review

Cano

Silva-Rojas

2023

Narra X

View full text Add to dashboard Cite

Microorganisms of the genus Achromobacter have been mentioned as a cause of opportunistic infections, mainly in patients with cystic fibrosis or pulmonary lymphoma, with the species Achromobacter xylosoxidans being identified to a large extent. A. xylosoxidans was first described in 1971 and is an opportunistic pathogen. However, it been reported to cause chronic purulent otitis, meningitis, pneumonia, peritonitis and urinary tract infections, chronic obstructive pulmonary disease and other infections. The present literature review aims to analyze and synthesize the state of the art on A. xylosoxidans and its potential as an emerging pathogen in the healthcare settings. We discuss A. xylosoxidans as an emerging opportunistic pathogen that is associated with healthcare infections. This review further discusses the prevalence of A. xylosoxidans in healthcare settings, the types of infections it can cause, and the risk factors for acquiring an A. xylosoxidans infection. The review also covers the challenges in treating A. xylosoxidans infections, including its potential for drug resistance and the lack of specific treatments. Strategies for preventing and controlling A. xylosoxidans infections in healthcare settings were also discussed.

show abstract

An Unusual Skin Infection With Achromobacter xylosoxidans

Cited by 4 publications

References 6 publications

Enigmatic Achromobacter

Enigmatic Achromobacter

Green Nail Syndrome Treated with Ozenoxacin: Two Case Reports

Achromobacter xylosoxidans as emerging pathogen in healthcare settings: A mini review

Contact Info

Product

Resources

About